Participants in the 72-week STEP UP trial who received the increased Wegovy dose of 7.2 mg experienced a mean weight reduction of 21%, while a third of them reached 25% body weight loss. Adults with ...

Higher dose of Wegovy ® provided average weight loss of 21% in people with obesity - with a third achieving 25% or more - according to data presented at ADA. Results from the phase 3b STEP UP trial ...

In the STEP UP trial, the higher dose of Wegovy ® (semaglutide 7.2 mg) demonstrated a mean weight loss of 21%, with a third of participants losing 25% or more of their body weight compared to ...

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss effects that weren’t as strong as previously reported.

Novo Nordisk A/S scrapped a partnership with Hims & Hers Health Inc. after less than two months, saying the US company is ...

Below are a few more promising studies of weight-loss drugs. Combining bimagrumab, an investigational human monoclonal antibody that binds to and inhibits activin receptor type-2B, with semaglutide ...

This new pill works by triggering the metabolism in the muscles, activating them to burn more fat, without the ...

Positive news from the laboratory was the wind beneath the wings of Novo Nordisk (NYSE: NVO) stock on Thursday. The ...

Novo Nordisk ( NVO 6.12%) stock, maker of the blockbuster GLP-1 agonist weight-loss drugs Ozempic and Wegovy, jumped a lucky 7% through 12:20 p.m. ET Tuesday after London's Financial Times reported ...

A monthly weight loss drug from Amgen helped people lose about 20% of their body weight, according to the results of a phase ...

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...

Novo Nordisk is progressing both subcutaneous and oral versions of amycretin into Phase III trials for patients with obesity ...